SMO and basal cell carcinoma: Inactivating mutations in PTCH1 and activating mutations in SMO have been detected in 73% or 20%, respectively, of patients with basal cell carcinoma (BCC), a stem cell-based malignancy accounting for ~90% of all solid tumors.